Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Ipsen (I7G) Stock Price & Analysis

1 Followers

I7G Stock Chart & Stats

€163.30€5.60(4.21%)
At close: 5:30 PM GMT+1
€140€150€160€170Jul 17Aug 4Aug 12Aug 25Sep 8Oct 2Oct 15
Day’s Range
EUR 163.30 - EUR 163.30
52-Week Range
EUR 116.20 - EUR 172.70
Previous Close
EUR 156.70
Volume
N/A
Average Volume (3M)
23
Market Cap
EUR 13.73B
Enterprise Value
EUR 12.99B
Total Cash (Recent Filing)
EUR 1.97B
Total Debt (Recent Filing)
EUR 963.20M
Price to Earnings (P/E)
27.0
Beta
0.44
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
8.28
Next Dividend Ex-Date
N/A
Dividend Yield
0.98%

Bulls Say, Bears Say

Bulls Say

Sustained Revenue Growth

Consistent multi-year revenue expansion indicates durable demand for Ipsen’s specialty medicines and continued commercial execution across its markets. The stronger 2025 performance increases the company’s scale and provides a foundation for funding clinical development, lifecycle management, and further portfolio growth.

Healthy Profitability

Ipsen remains meaningfully profitable despite margin pressure, with a 30% EBITDA margin demonstrating substantial earnings capacity from its specialty pharmaceutical portfolio. This profitability can support reinvestment in development and commercialization while providing resilience through changes in product mix or reimbursement.

Conservative Leverage And Improved Cash Flow

Low debt relative to equity supports financial resilience and preserves flexibility for investment, partnerships, or shareholder returns. The strong 2025 free-cash-flow rebound, which closely matched earnings, also indicates that the business can convert substantial profitability into internally generated funding.

Bears Say

Meaningful Margin Compression

The substantial reduction in net margin shows that revenue growth has not translated proportionally into bottom-line expansion. If higher costs or unfavorable mix persist, Ipsen may have less capacity to reinvest in its pipeline, absorb pricing pressure, or convert commercial growth into durable earnings growth.

Sharp Increase In Total Debt

The rapid increase in total debt is a developing balance-sheet risk even though overall leverage remains conservative. Greater obligations can reduce financial flexibility, increase financing costs, and make future capital allocation more dependent on sustained operating performance and reliable cash generation.

Volatile Cash-Flow Conversion

Uneven cash-flow conversion makes the timing and reliability of internally generated funds less predictable than reported earnings alone suggest. This variability can complicate investment planning and debt management, particularly if working-capital or execution pressures recur after the strong 2025 rebound.

Ipsen News

I7G FAQ

What was Ipsen’s price range in the past 12 months?
Ipsen lowest stock price was €116.20 and its highest was €172.70 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is €13.73B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 91 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Jul 30, 2026. The company reported €7.33 earnings per share for the quarter, beating the consensus estimate of €6.32 by €1.01.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Undervalued.
Does Ipsen pay dividends?
Ipsen does not currently pay dividends.
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate is 8.28.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of €7.33 in its last earnings report, beating expectations of €6.32. Following the earnings report the stock price went up 3.66%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in DE:I7G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology